Is London's AIM the New Nasdaq? Not Yet.

Some observers see London's ten-year old junior market for high-growth, small-to-mid-cap companies as, if not a Nasdaq-in-waiting, then certainly the most likely exchange to rival it. But although AIM is attracting growing numbers of overseas companies, some sheltering from Sarbanes-Oxley, liquidity and follow-on financing issues remain. AIM isn't Europe's Nasdaq, not yet.

Usually, biopharma firms in Europe that are struggling to raise money turn to the US, either for a listing or re-location, or for both. So the decision by California-based Entelos Inc. to float not at home but on London's Alternative Investment Market (AIM), where it recently raised $20 million, highlights an interesting counter current. [See Deal] It also fueled the enthusiasm of some London-based bankers and analysts who increasingly see London's 10-year-old junior market for high-growth, small-to-mid-cap companies as, if not a Nasdaq-in-waiting, then certainly the most likely exchange to rival it. Some say AIM will eventually become the pan-European exchange that others such as Euronext (the combined Brussels, Paris, and Amsterdam markets), Nasdaq Europe, and Easdaq have tried but failed to achieve. (See "Easdaq: Fighting for a Lost Cause?" START-UP, January 2001 Also see "EASDAQ: Fighting for a Lost Cause?" - Scrip, 1 January, 2001..)

The statistics are indeed compelling. The total market capitalization of AIM-listed companies (which span all sectors) has increased by 80%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By 

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By 

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

More from Business

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By 

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut